{"name":"Beijing Shenogen Biomedical Co., Ltd","slug":"beijing-shenogen-biomedical-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"HUACHANSU PIAN","genericName":"HUACHANSU PIAN","slug":"huachansu-pian","indication":"Cancer (various types, traditional indication)","status":"phase_3"},{"name":"Sorafenib Tosylate Tablets","genericName":"Sorafenib Tosylate Tablets","slug":"sorafenib-tosylate-tablets","indication":"Advanced renal cell carcinoma","status":"phase_3"}]}],"pipeline":[{"name":"HUACHANSU PIAN","genericName":"HUACHANSU PIAN","slug":"huachansu-pian","phase":"phase_3","mechanism":"Huachansu is a traditional Chinese medicine extract derived from toad secretions that contains bufadienolides and other bioactive compounds with potential anti-tumor and immunomodulatory properties.","indications":["Cancer (various types, traditional indication)","Cardiac arrhythmias (traditional use)"],"catalyst":""},{"name":"Sorafenib Tosylate Tablets","genericName":"Sorafenib Tosylate Tablets","slug":"sorafenib-tosylate-tablets","phase":"phase_3","mechanism":"Sorafenib Tosylate Tablets inhibit multiple intracellular and cell surface kinases, which are involved in tumor growth and angiogenesis.","indications":["Advanced renal cell carcinoma","Advanced hepatocellular carcinoma","Advanced radioactive iodine-refractory differentiated thyroid cancer"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}